CheckMate 816: Association of Pathologic Regression With EFS for Neoadjuvant Nivolumab + CT in Resectable NSCLC

Source: 2022 ASCO Annual Meeting*
Download Slideset
June 3-7, 2022; Chicago, Illinois
In a post hoc analysis of CheckMate 816, pCR or major pathologic response in the primary tumor was associated with improved EFS with neoadjuvant nivolumab + chemotherapy and chemotherapy in resectable NSCLC.
Format: Microsoft PowerPoint (.ppt)
File Size: 249 KB
Released: June 10, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Jazz Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings